BioCentury
ARTICLE | Emerging Company Profile

Innodia: Surrounding diabetes

July 18, 2005 7:00 AM UTC

In a slight twist on the typical NRDO business model, Innodia Inc. has no internal research capabilities of its own, relying on a network of academic and corporate partnerships to in-license Type II diabetes candidates that are within 18 months of an IND. Its strategy is to develop an array of oral small molecules to treat and prevent the disease from a different angle.

President and CEO Claude Vezeau believes a key to success will be the variety of targets that will allow the company to "broaden the way in which diabetes is attacked." ...